This study is testing a new treatment called CTX112 for adults with severe autoimmune diseases like lupus (SLE), lupus nephritis, systemic sclerosis, or inflammatory myopathy, when other treatments haven't worked. CTX112 is a type of immunotherapy that uses specially modified immune cells from a healthy donor to target specific cells in your body. The main goal of this study is to see how safe CTX112 is in the first 28 days after you receive it. Researchers also want to see if it helps improve your condition. You may be able to join if you are between 18 and 70 years old and meet certain health requirements. Up to 80 people may participate in this study.

Study design

This is an early-stage study where all participants will receive CTX112. It is an open-label study, meaning both you and your doctors will know you are receiving the treatment. Up to 80 people will be enrolled.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be checked for at least 28 days after you receive the CTX112 infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.